In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Browsing: Clinical > Antimicrobial Resistance
Nearly half of prescriptions for antibiotics were written without an infection-related diagnosis, according to a study of 509,534 prescriptions reported at IDWeek today.
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
Researchers from Genentech have carried out optimization of the arylomycins, uncovering a molecule with potent, broad-spectrum activity against Gram-negative bacteria.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on the emergence of antifungal resistance and what can be done in response with author, Justin Beardsley.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on antibiotic resistance targets for point-of-care diagnostics with author, John P. Hays.
Over 8000 combinations of four of five antibiotics have been demonstrated to be more effective than previously thought, according to new research.
The European Gonococcal Antimicrobial Surveillance Programme has revealed high levels of azithromycin resistance in Europe, however, these have remained relatively stable.